She has a profound interest in dissecting the molecular mechanisms involved in the development of CRC as well as in the different drug resistance mechanisms by focusing on the metabolic changes in tumor cells and in the cells of the microenvironment (stromal cells and microbioma). Together with different hospitals, the Integrated BioBank of Luxembourg (IBBL) and the Laboratoire National de la Santé (LNS), she has been the driving force to develop an ongoing collection of tumor tissue samples from CRC patients, assembling so far over 180 high quality patient samples. Elisabeth Letellier and her team have established patient-derived 3D tumor models, as well as in vivo models, to perform high quality translational research.
She has authored more than 40 publications in related topics in distinguished journals (H index: 27, citations: 3196) and since 2013, she has been able to secure more than 9 M€, the large majority being from external competitive funds. She has contributed to three patent filing, two of them as the main author.
